SynAct Pharma to attend BIO-Europe in Stockholm November 4-6
SynAct Pharma AB (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, today announces the company plans to attend BIO-Europe in Stockholm from November 4-6.
SynAct’s management team is attending the partnering event to discuss the company’s ongoing Phase 2b ADVANCE clinical trial studying its lead drug candidate resomelagon (AP1189) in patients with newly diagnosed severe rheumatoid arthritis.
About BIO-Europe
BIO-Europe is one of the largest partnering events in Europe, bringing together more than 5,500 delegates to participate in over 30,000 one-to-one meetings, and is a key platform connecting the global biopharma community.